PMC:6909918 / 11904-13223 JSONTXT

{"project":"2_test","denotations":[{"id":"31790382-19631507-69134701","span":{"begin":92,"end":94},"obj":"19631507"},{"id":"31790382-23177514-69134702","span":{"begin":749,"end":750},"obj":"23177514"},{"id":"31790382-25970050-69134702","span":{"begin":749,"end":750},"obj":"25970050"},{"id":"31790382-29215955-69134702","span":{"begin":749,"end":750},"obj":"29215955"},{"id":"31790382-29946728-69134702","span":{"begin":749,"end":750},"obj":"29946728"},{"id":"31790382-25981818-69134703","span":{"begin":753,"end":755},"obj":"25981818"},{"id":"31790382-23177514-69134704","span":{"begin":865,"end":866},"obj":"23177514"},{"id":"31790382-25970050-69134705","span":{"begin":921,"end":922},"obj":"25970050"},{"id":"31790382-29215955-69134706","span":{"begin":1048,"end":1049},"obj":"29215955"},{"id":"31790382-29946728-69134707","span":{"begin":1189,"end":1190},"obj":"29946728"},{"id":"31790382-25981818-69134708","span":{"begin":1315,"end":1317},"obj":"25981818"}],"text":"Systematic review of the literature\nFigure 1 shows the flow diagram of the study selection [10]. All the included published studies were randomized and placebo-controlled in design and were in accordance with the inclusion criteria of the present study for patients with refractory metastatic colorectal cancer (mCRC). A systematic review of the published literature initially identified 767 potential publications. Following removal of meeting abstracts, duplicated publications, and studies that were not randomized placebo-controlled trials, the final publications were read and reviewed in full by the investigators.\nFive published clinical trials, which included 2,604 patients with refractory mCRC, were considered eligible for meta-analysis [4–7,11]. The published studies included: the CORRECT Trial, of regorafenib monotherapy for previously treated mCRC [4]; the RECOURSE Trial, of TAS-102 for refractory mCRC [5]; the TERRA phase III trial, of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated mCRC [6]; the FRESCO Trial, of the effect of fruquintinib compared with placebo on overall survival (OS) in patients with previously treated mCRC [7]; the CONCUR trial, of regorafenib plus best supportive care versus placebo in Asian patients with previously treated mCRC [11]."}